TScan Therapeutics
TCRX
25 hedge funds and large institutions have $26.3M invested in TScan Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.44% less ownership
Funds ownership: 52.94% → 50.5% (-2.4%)
14% less funds holding
Funds holding: 29 → 25 (-4)
41% less capital invested
Capital invested by funds: $44.4M → $26.3M (-$18M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$865K |
| 2 |
Barclays
London,
United Kingdom
|
+$687K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$324K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$160K |
| 5 |
BlackRock
New York
|
+$89.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$2.65M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.01M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$219K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$115K |
| 5 |
HF
HRT Financial
New York
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
26
CAAS Capital Management
New York
| – | -$115K | -25,633 | Closed |
|
|
HF
27
HRT Financial
New York
| – | -$93K | -20,829 | Closed |
|
28
LPL Financial
San Diego,
California
| – | -$59K | -13,000 | Closed |
|
29
Millennium Management
New York
| – | -$55K | -12,276 | Closed |
|
30
Jane Street
New York
| – | -$51K | -11,307 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$4K | -811 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$1K | -189 | Closed |
|
TCRX Hedge Fund Activity: Q1 2022 in Review
25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2022, worth a combined $26.3M — down 41% from $44.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TCRX and 4 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $865K. The largest seller was HHLR Advisors, cutting an estimated $2.65M.
- 25 institutional investors held TScan Therapeutics (TCRX) as of Q1 2022, down from 29 in Q4 2021.
- Funds reported $26.3M of TScan Therapeutics stock for Q1 2022, down 41% quarter-over-quarter.
- 4 funds opened new TScan Therapeutics positions in Q1 2022 and 8 closed out, a net change of -4 holders.
- The largest TScan Therapeutics buyer in Q1 2022 was Tang Capital Management, an estimated $865K added.
- The largest TScan Therapeutics seller in Q1 2022 was HHLR Advisors, an estimated $2.65M sold.
Based on aggregated 13F filings for Q1 2022.